Assembly Biosciences
Patrick Kennedy is a Professor of Translational Hepatology & Consultant Hepatologist at Barts and The London School of Medicine & Dentistry, QMUL.
Dr. Kennedy’s primary research focus is in HBV with a special interest in liver disease in young people. He runs a dedicated young adult clinic at The Royal London Hospital and leads the HBV service at Bart’s Health with more than 6,000 chronic HBV infected patients. He has produced novel work redefining disease phase in HBV, the foundation for the re-evaluation of treatment candidacy. Developing these research avenues is an important focus of his current work towards individualized treatment strategies and changing the current management paradigm in CHB.
Currently, Dr. Kennedy leads the UK special interest group (SIG) in HBV, is the secretary of the British Viral Hepatitis Group (BVHG), an expert advisor for NICE and a member of the viral hepatitis clinical guideline committee for CHB. He provides expert opinion for the United Kingdom Advisory Panel on blood-borne viruses and is the Hepatology lead for the Gastroenterology and Hepatology Section at the Royal Society of Medicine.
Dr. Kennedy trained at University College Dublin and completed post-graduate training in Gastroenterology & Hepatology in London, and in 2009 was appointed as a HEFCE Clinical Senior Lecturer at Barts and The London Medical School.
This person is not in the org chart
This person is not in any offices
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.